Neurohealing receives FDA orphan drug designation for NH001 for the treatment of patients in a vegetative state or minimally conscious state following brain injury
Newton, Mass., May 25, 2006 NeuroHealing Pharmaceuticals, Inc. today announced that the Office of Orphan Products Development of the U.S. Food and Drug Administration (FDA) has granted orphan drug status to NH001 for the treatment of patients in a vegetative state or minimally conscious state for up to twelve months following a brain injury (traumatic…
Details